IP Library › Patent Application 14616625
Patent Application
App. No. 14/616,625

Abiraterone Steroid Formulation

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/616,625
Abstract

A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.

Claims (4)

1 . A method of treating prostate cancer comprising administering a glucocorticoid and a daily dose of between 400 and 600 mg of abiraterone acetate.

2 . The method of claim 1 wherein the abiraterone acetate has a median particle size on a volume average basis of 100 nm-1000 nm.

3 . The method of claim 1 wherein the glucocorticoid is methylprednisolone.

4 . The method of claim 1 wherein the daily dose of abiraterone acetate is administered as a single dose.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: CHURCHILL INTERMEDIATE INC.; CHURCHILL PHARMACEUTICALS LLC
To: SUN PHARMA GLOBAL FZE
Reel/Frame 047137/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2015
From: NEMETH, PAUL; CALLAHAN, MATT; BOSCH, H. WILLIAM
To: ICEUTICA INC.
Reel/Frame 034940/0438 →